Compare CMP & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CMP | SLBT |
|---|---|---|
| Founded | 1993 | N/A |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 999.1M | 942.1M |
| IPO Year | 2003 | 2025 |
| Metric | CMP | SLBT |
|---|---|---|
| Price | $22.19 | $1.88 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $21.50 | N/A |
| AVG Volume (30 Days) | ★ 328.9K | 102.8K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.29 | N/A |
| P/E Ratio | $37.95 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.40 | $1.42 |
| 52 Week High | $34.50 | $6.25 |
| Indicator | CMP | SLBT |
|---|---|---|
| Relative Strength Index (RSI) | 28.04 | 41.45 |
| Support Level | $20.83 | N/A |
| Resistance Level | $26.72 | $3.36 |
| Average True Range (ATR) | 0.60 | 0.22 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 12.85 | 41.59 |
Compass Minerals currently produces two primary products: salt and specialty potash fertilizer. The company's main assets include rock salt mines in Ontario, Louisiana, and the United Kingdom. The fertilizer is produced from a brine operation at the Great Salt Lake in Utah that produces sulfate of potash and magnesium chloride. Compass' salt products are used for deicing and also by industrial and consumer end markets. The firm's sulfate of potash is used by growers of high-value crops that are sensitive to standard potash.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.